Revenue -4% in constant exchange rates to $6.84B, just above forecasts of $6.82B.
Adjusted profit fell 26% to $1.98B, dragged down by patent expirations on key drugs.
The loss of IP protection will continue to hurt the company, and it forecasts that 2014 revenue will drop by a low-to-mid single digit percentage and that EPS will decline "in the teens."
AstraZeneca declared a second interim dividend of $1.90 a share. (PR)